**The Cooper Companies, Inc. (COO) reported fiscal 2025 revenues of $2.74 billion from its CooperVision segment and $1.35 billion from CooperSurgical, highlighting the dual-segment model’s importance in driving overall growth. The company anticipates sales growth of over 5% for both fiscal 2026 and 2027. However, a decline of 6% in the Asia-Pacific region to $130.6 million in the second quarter of fiscal 2026 poses challenges, attributed to weaknesses in China, Japan, and Korea.**
**MiSight’s revenue grew 24% to $32 million in the same quarter, driven by its unique position in pediatric myopia control as the only FDA-approved lens for slowing myopia progression in children. Despite a positive growth outlook, COO faces pressure from macroeconomic factors affecting gross margins, which are expected to stabilize around 66%. Earnings per share are projected to improve by 12.4% in fiscal 2026.**
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
